Overview of the Role of Tyrosine Protein Kinases and Their Inhibitors in Cancer Disease
DOI:
https://doi.org/10.53555/ejac.v20i2.1189Keywords:
Tyrosine kinase inhibitors, cancer, phosphorylation, dimerization.Abstract
Tyrosine-protein Kinases are considered primary targets for drug development due to their amplification in several tumorigenesis and uncontrolled proliferation. Their function is to phosphorylate their substrates' tyrosine residues, which are inhibited by tyrosine kinase inhibitors (TKIs), consequently blocking the intracellular signaling currents.
Over the last two decades, the development process of TKIs has been successful in introducing various influential and well-tolerated one-target and multiple targets agents such as FGFR, MEK, MET, RET, VEGFR, NTRK, HER2, ROS1, ALK, EGFR.
In this article, we summarize the valuable information about tyrosine kinases and their inhibitors to obtain the maximum possible benefit, to get a therapeutic substance with high efficiency and effectiveness, with few side effects, to achieve the maximum benefit for human society, and to gain the most extended possible period of survival for people with malignant tumors
In conclusion, cancer patients' survival and quality of life have significantly improved through the discovery and continuous development of TKIs, transforming the treatment guidelines for various cancer diseases.
References
Alves R, Gonçalves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance. Cancers. 2021 Sep 26;13(19):4820. https://doi.org/10.3390/cancers13194820
Arter C, Trask L, Ward S, Yeoh S, Bayliss R. Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. Journal of Biological Chemistry. 2022 Aug 1;298(8). https://doi.org/10.1016/j.jbc.2022.102247
Berndt, S. and Liebscher, I., 2021. New structural perspectives in G protein-coupled receptor-mediated Src family kinase activation. International Journal of Molecular Sciences, 22(12), p.6489. https://doi.org/10.3390/ijms22126489.
Choi, H.Y. and Chang, J.E., 2023. Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs. International Journal of Molecular Sciences, 24(17), p.13618. https://doi.org/10.3390/ijms241713618
Cooke M, Magimaidas A, Casado‐Medrano V, Kazanietz MG. Protein kinase C in cancer: The top five unanswered questions. Molecular carcinogenesis. 2017 Jun;56(6):1531-42. doi: 10.1002/mc.22617.
Crisci S, Amitrano F, Saggese M, Muto T, Sarno S, Mele S, Vitale P, Ronga G, Berretta M, Di Francia R. Overview of current targeted anti-cancer drugs for therapy in onco-hematology. Medicina. 2019 Jul 28;55(8):414. https://doi.org/10.3390/medicina55080414
Du Y, Hsu JL, Wang YN, Hung MC. Nuclear functions of receptor tyrosine kinases. InReceptor Tyrosine Kinases: Structure, Functions and Role in Human Disease 2014 Oct 30 (pp. 77-109). New York, NY: Springer New York. https://doi.org/10.1007/978-1-4939-2053-2_5.
El-Naggar AM, Hassan AM, Elkaeed EB, Alesawy MS, Al‐Karmalawy AA. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. Bioorganic Chemistry. 2022 Jun 1;123:105770. https://doi.org/10.1016/j.bioorg.2022.105770
Fabbro D, Cowan‐Jacob SW, Moebitz H. Ten things you should know about protein kinases: IUPHAR R eview 14. British journal of pharmacology. 2015 Jun;172(11):2675-700. https://doi.org/10.1111/bph.13096
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. InSeminars in cancer biology 2022 Feb 1, 79, 180-196. https://doi.org/10.1016/j.semcancer.2020.11.013
Gupta D, Kumar M, Saifi S, Rawat S, Ethayathulla AS, Kaur P. A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics. International Journal of Biological Macromolecules. 2024 Mar 18:130913. https://doi.org/10.1016/j.ijbiomac.2024.130913.
Glaviano A, Foo AS, Lam HY, Yap KC, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular cancer. 2023 Aug 18;22(1):138. https://doi.org/10.1186/s12943-023-01827-6.
Hossain, M.A., 2024. Targeting the RAS upstream and downstream signaling pathway for Cancer treatment. European Journal of Pharmacology, p.176727. https://doi.org/10.1016/j.ejphar.2024.176727
Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). Journal of hematology & oncology. 2020 Dec;13:1-23. https://doi.org/10.1186/s13045-020-00977-0.
K. Bhanumathy K, Balagopal A, Vizeacoumar FS, Vizeacoumar FJ, Freywald A, Giambra V. Protein tyrosine kinases: their roles and their targeting in leukemia. Cancers. 2021 Jan 7;13(2):184. https://doi.org/10.3390/cancers13020184.
Lin, C.C., Suen, K.M., Lidster, J. and Ladbury, J.E., 2024. The emerging role of receptor tyrosine kinase phase separation in cancer. Trends in Cell Biology, 34(5), pp.371-379. https://doi.org/10.1016/j.tcb.2023.09.002.
López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer cell. 2017 Aug 14;32(2):135-54. https://doi.org/10.1016/j.ccell.2017.06.009.
Milon TI, Rauniyar K, Furman S, Orthi KH, Wang Y, Raghavan V, Xu W. Representing and Quantifying Conformational Changes of Kinases and Phosphatases Using the TSR-Based Algorithm. Kinases and Phosphatases. 2024 Nov 8;2(4):315-39. https://doi.org/10.3390/kinasesphosphatases2040021
Montoya, S., Soong, D., Nguyen, N., Affer, M., Munamarty, S. P., & Taylor, J. (2021). Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines, 9(11), 1591. https://doi.org/10.3390/biomedicines9111591
Mortezaee K, Salehi E, Mirtavoos‐mahyari H, Motevaseli E, Najafi M, Farhood B, Rosengren RJ, Sahebkar A. Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. Journal of cellular physiology. 2019 Aug;234(8):12537-50. https://doi.org/10.1002/jcp.28122.
Nachmias B, Aumann S, Haran A, Schimmer AD. Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights. British Journal of Haematology. 2024 Apr;204(4):1146-58. https://doi.org/10.1111/bjh.19314
Nishal, S., Jhawat, V., Gupta, S. and Phaugat, P., 2023. Utilization of kinase inhibitors as novel therapeutic drug targets: A review. Oncology research, 30(5), p.221. https://doi.org/10.32604/or.2022.027549.
Patel, V.K., Shirbhate, E., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A. and Rajak, H., 2023. Multi-targeted HDAC inhibitors as anticancer agents: current status and future prospective. Current Medicinal Chemistry, 30(24), pp.2762-2795. https://doi.org/10.2174/0929867329666220922105615.
Roskoski Jr R. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological research. 2019 Jun 1;144:19-50. https://doi.org/10.1016/j.phrs.2024.107059.
Sankarapandian V, Rajendran RL, Miruka CO, Sivamani P, Maran BA, Krishnamoorthy R, Gangadaran P, Ahn BC. A review on tyrosine kinase inhibitors for targeted breast cancer therapy. Pathology-Research and Practice. 2024 Sep 25:155607. https://doi.org/10.1016/j.prp.2024.155607
Saraon, P., Pathmanathan, S., Snider, J., Lyakisheva, A., Wong, V. and Stagljar, I., 2021. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene, 40(24), pp.4079-4093. https://doi.org/10.1038/s41388-021-01841-2
Scholl, S.; Fleischmann, M.; Schnetzke, U.; Heidel, F.H. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. Cells 2020, 9, 2493. https://doi.org/10.3390/cells9112493.
Siveen KS, Prabhu KS, Achkar IW, Kuttikrishnan S, Shyam S, Khan AQ, Merhi M, Dermime S, Uddin S. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Molecular cancer. 2018 Dec;17:1-21. https://doi.org/10.1186/s12943-018-0788-y
Stehle, J., Weisner, J., Eichhorn, L., Rauh, D. and Drescher, M., 2023. Insights into the Conformational Plasticity of the Protein Kinase Akt1 by Multi‐Lateral Dipolar Spectroscopy. Chemistry–A European Journal, 29(24), p.e202203959. https://doi.org/10.1002/chem.202203959
Suryavanshi A, Vandana, Shukla YK, Kumar V, Gupta P, Asati V, Mahapatra DK, Keservani RK, Jain SK, Bharti SK. MEK inhibitors in oncology: a patent review and update (2016–present). Expert Opinion on Therapeutic Patents. 2024 Oct 2;34(10):963-1007.
Tomuleasa, C., Tigu, A.B., Munteanu, R., Moldovan, C.S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H. and Croce, C.M., 2024. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduction and Targeted Therapy, 9(1), p.201. https://doi.org/10.1038/s41392-024-01899-w.
Wendler F, Purice TM, Simon T, Stebbing J, Giamas G. The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2021 Sep 1;1867(9):165372. https://doi.org/10.1016/j.bbadis.2018.12.023
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2017 Nov 1;18(11):1454-66. https://doi.org/10.1016/s1470-2045(17)30608-3
Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal transduction and targeted therapy. 2022 Sep 17;7(1):329. https://doi.org/10.1038/s41392-022-01168-8.
Zámečníkova A. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. Expert opinion on drug discovery. 2014 Jan 1;9(1):77-92. https://doi.org/10.1517/17460441.2014.865012
Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, Huang H, Zhao Y. TP53 in MDS and AML: biological and clinical advances. Cancer Letters. 2024 Feb 27:216767. https://doi.org/10.1016/j.canlet.2024.216767
